What information about trichomoniasis should patients receive?

Updated: Jan 02, 2020
  • Author: Darvin Scott Smith, MD, MSc, DTM&H; Chief Editor: Michael Stuart Bronze, MD  more...
  • Print

Education concerning STI treatment and prevention is vital (see Prevention). Because T vaginalis infection is strongly associated with the presence of other STIs (gonorrhea, [52] chlamydia, and sexually transmitted viruses such as HIV), providers should provide appropriate counseling, testing, and treatment for such infections.

Upon diagnosis of trichomoniasis, healthcare providers should discuss treatment, including the adverse effects and interactions encountered with metronidazole and tinidazole. It is especially important to warn patients to abstain from alcohol when taking metronidazole and tinidazole. Providers should also address the treatment of sexual partners and, where allowed by law, employ expedited partner therapy. Individuals with trichomoniasis who notify partners of their infection help disrupt the transmission of trichomoniasis and other STIs. [57]

Providers should also discuss methods of preventing T vaginalis reinfection. It may be important to explain that T vaginalis infection may be longstanding and not due to a recent sexual encounter.

The CDC advises providers to consider rescreening sexually active women at 3 months after the completion of treatment. [48] Currently, the CDC makes no recommendation regarding the rescreening of sexually active men, but it may be desired if reinfection is likely. [11]

The CDC does not take a definitive stance on treating trichomoniasis during pregnancy. Studies have shown both positive and negative outcomes of treatment with a single 2-gram dose of metronidazole. Physician discretion is advised. [11] See the patient education fact sheet below.

Patient education fact sheet on trichomoniasis. Patient education fact sheet on trichomoniasis.

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!